阿斯利康(AZN.US)預防新冠抗體藥進入內地市場 於博鰲先行先試
內媒報道,海南海口海關公布,博鰲機場海關日前為內地首次進口的中和抗體Evusheld(恩適得)完成入境特殊物品審批,貨值共計2,198萬元人民幣。該藥由英國藥廠阿斯利康(AZN.US)研發,主要用於成人和青少年的新型冠狀病毒肺炎暴露前預防。
藥物落地醫院博鰲樂城瑞金海南醫院技術拓展部負責人王芳介紹指,Evusheld在海南獲批,標誌目前全球唯一一款可以用於新型冠狀病毒感染預防的藥物,在內地首次先行先試准入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.